2024-01-04 07:23:57 ET
DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- Omega Therapeutics, Inc. (NASDAQ: OMGA) announced, this morning, along with Novo Nordisk and Cellarity Inc. that Novo Nordisk entered into separate research collaborations with each company, with the Omega collaboration leveraging its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity’s platform to develop a small molecule therapy against this disease.
Omega Therapeutics is trading at $4.33, up $1.60 (+58.61%), on 1.4M shares traded. Its 52-week range is $1.30 to 11.98. This morning’s volume is on pace to easily set a …
The post Research Collaborations on Novel Treatment Approaches for Cardiometabolic Diseases has this Listing Racing appeared first on 24/7 Market News .
For further details see:
Research Collaborations on Novel Treatment Approaches for Cardiometabolic Diseases has this Listing Racing